Related Experiment Video

Updated: Aug 9, 2026

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene

Zhuo Zhang1, Mao Li, Hui Wang

  • 1Department of Pharmacology and Toxicology and Comprehensive Cancer Center, University of Alabama at Birmingham, VH 113, 1670 University Boulevard, Birmingham, AL 35294, USA.

Proceedings of the National Academy of Sciences of the United States of America
|September 18, 2003
PubMed

Insights

This study shows that inhibiting the mouse double minute 2 (MDM2) oncogene reduces prostate cancer growth and increases chemotherapy effectiveness. MDM2 inhibitors offer a promising new therapy approach for prostate cancer, regardless of p53 status.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • The mouse double minute 2 (MDM2) oncogene plays a role in cancer development.
  • Targeting MDM2 is a potential therapeutic strategy for various cancers.
  • Understanding MDM2's role in prostate cancer is crucial for developing new treatments.

Purpose of the Study:

  • To investigate the role of the MDM2 oncogene in prostate cancer progression.
  • To evaluate the therapeutic potential of targeting MDM2 in human prostate cancer models.
  • To explore MDM2's influence on gene expression and cell behavior in prostate cancer.

Main Methods:

  • Utilized an antisense anti-human-MDM2 mixed-backbone oligonucleotide.
  • Tested the oligonucleotide in human prostate cancer cell lines (LNCaP, DU145, PC3) with different p53 statuses.
  • Analyzed gene and protein expression levels, cell proliferation, apoptosis, and xenograft tumor growth.

Main Results:

  • MDM2 inhibition reduced prostate cancer cell proliferation and induced apoptosis.
  • Observed significant changes in the expression of key genes (p53, p21, Bax, Bcl2, pRb, E2F1) involved in cell cycle regulation and apoptosis.
  • The anti-MDM2 oligonucleotide demonstrated antitumor activity in xenografts and enhanced the efficacy of paclitaxel.

Conclusions:

  • MDM2 is implicated in prostate cancer growth through both p53-dependent and p53-independent pathways.
  • MDM2 inhibitors, such as antisense oligonucleotides, exhibit broad-spectrum antitumor activity.
  • Targeting MDM2 presents a novel therapeutic avenue for prostate cancer, irrespective of p53 mutation status.

More Related Videos

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...